VivoSeq
Other

Metabolic Dysfunction-Associated Steatohepatitis (MASH)

6

Pipeline Programs↗

3

Active Trials↗

4

Companies Involved↗

Metabolic Dysfunction-Associated Steatohepatitis (MASH) is an early-stage landscape with 6 programs across 4 companies. The most active players are Fujian Shengdi Pharmaceutical Co., Ltd., Alnylam Pharmaceuticals, Eli Lilly. 1 therapy is approved.

Intelligence

Pipeline Metrics

Competitive Density

32/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

F

Fujian Shengdi Pharmaceutical Co., Ltd.

4 programs

Phase 2Alnylam Pharmaceuticals logo

Alnylam Pharmaceuticals

1 program

Phase 2Eli Lilly logo

Eli Lilly

2 programs

Phase 2Regeneron logo

Regeneron

0 programs

Preclinical

Pipeline

Programs by Phase

Analysis

Trial Status

4

clinical trials

Not yet recruiting2 · 50%
Recruiting1 · 25%
Completed1 · 25%

Clinical Trials

Trial Activity

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors
Recruiting·Regeneron logoRegeneron·Phase 2·NCT05519475·120 enrolled
Assessing Nutrition-aligned Resmetirom Roll-out
Not yet recruiting·City University of New York·Approved·NCT07680478·120 enrolled
A Single-Ascending and Repeated Subcutaneous Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3849891 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Who Have the PNPLA3 I148M Genotype
Completed·Eli Lilly logoEli Lilly·Phase 1·NCT05395481·115 enrolled
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Master Protocol Clinical Trial to Investigate the Efficacy and Safety of HRS-4729 Injection and HRS9531 Injection in Adult Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Not yet recruiting·FFujian Shengdi Pharmaceutical Co., Ltd.·Phase 2·NCT07660848·160 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)